Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX) and ChemoGLO announced a strategic collaboration to expand hazardous drug contamination testing for health care facilities and laboratories.

The partnership pairs the BD HD Check System — providing qualitative, point-of-care results in 10 minutes — with ChemoGLO's LC-MS/MS quantitative analysis, which delivers an expanded hazardous‑drug panel report within 3–5 days after sample receipt. The workflow uses BD HD Check collection kits for safe shipping to ChemoGLO for follow-up testing.

The combined approach aims to help facilities quickly identify contamination and gain deeper quantitative insights to better protect health care workers. BD and ChemoGLO will be at the ASHP Midyear Clinical Meeting in Las Vegas, Dec 6–10, 2025 (BD Booth 1017; ChemoGLO Booth 1873).

BD (NYSE:BDX) announced on Dec 3, 2025 new three- and four-laser configurations of the BD FACSDiscover A8 Cell Analyzer, expanding access to spectral and real-time cell imaging for academia, pharma and biotech.

Key features include BD SpectralFX (analyzes up to 50+ cell characteristics), BD CellView Image for high-speed spatial/morphological imaging, optional free trials and later software upgrades, and compatibility with BD sorters and new near-infrared fluorochromes. Instruments are available to order with flexible financing options.

BD (NYSE: BDX) announced the European launch of the BD Surgiphor Surgical Wound Irrigation System on November 24, 2025. The device received CE approval and is now available in select European countries. Surgiphor is a sterile, pre-mixed, ready-to-use irrigation solution that uses a trusted antiseptic preservative to help loosen and remove debris and reduce bacterial load in surgical wounds. BD says the product is designed to simplify wound irrigation, reduce preparation time, and support evidence-based practices to help lower the risk of surgical site infections and improve surgical safety.

Availability is limited to select countries in Europe; healthcare providers should contact BD sales representatives for regional access and product details.

BD (NYSE:BDX) announced a pharmacy automation partnership with Henry Ford Health on Sept. 22, 2025 to develop a hospital and community pharmacy robotic solution using the BD Rowa Vmax.

The collaboration will pilot 24/7 prescription pickup, automated high-capacity storage and refrigerated handling, real-time prescription tracking, and modular scalability to improve pharmacy staff efficiency and ensure patients leave with medications in hand at discharge or clinic visits.

BD (NYSE: BDX) announced the appointment of Robert Huffines and Jacqueline Wright to its board of directors, effective Dec. 1, 2025. The company said the additions add expertise in health care, technology, digital transformation, artificial intelligence, finance and capital markets as BD advances its strategy to be a scaled pure‑play medical technology company. BD added three new independent directors in 2025, reflecting ongoing board refreshment. Bios note Huffines' 30+ years in healthcare investment banking and board service, and Wright's 30+ years in technology and digital transformation at McKinsey and Microsoft.

BD (NYSE: BDX) announced that the CE-marked BD Onclarity HPV Assay for the BD COR and BD Viper LT systems received WHO prequalification on November 17, 2025, enabling wider use in low- and middle-income countries.

The assay detects 14 high-risk HPV types with extended genotyping (six individual types plus three genotype groups), supports self-collection including at-home where CE is recognized, and targets improved risk stratification and follow-up. The BD COR offers ~1,650-test capacity and up to 1,000 results in 24 hours; BD Viper LT provides compact, decentralized molecular testing.

BD (NYSE: BDX) announced on November 13, 2025 that Duncan Regional Hospital is the first U.S. hospital to go live with BD Alaris™ EMR Infusion Interoperability integrated with MEDITECH. The integration enables bi-directional communication between MEDITECH and Alaris infusion pumps, allowing clinicians to scan to verify patients, medications and pumps; send infusion orders from MEDITECH to pumps; and receive infusion status back into the EHR.

The rollout expands BD's market-leading interoperability—now live at more than 960 U.S. sites—to all three leading U.S. EHRs, and BD reports a pace of about 12 new site activations per month.

BD (NYSE: BDX) on Nov 12, 2025 introduced the PureWick™ Portable Collection System, a battery-powered, non-invasive urine management device designed for wheelchair users and mobile use.

Key facts: the device offers up to 8 hours battery life, is mountable or carriable, compatible with PureWick™ male and female external catheters, and is sold via PureWickAtHome.com and phone ordering. The PureWick portfolio has sold > 55 million external catheters and is used in > 4,500 hospitals and rehab facilities in the U.S.; a survey of 150 users/caregivers found > 90% would recommend the PureWick urine collection system. BD positions the portable unit to improve mobility, discretion, and skin protection for people managing urinary incontinence.

BD (NYSE: BDX) reported fiscal 2025 Q4 revenue of $5.9B (+8.3% reported, +7.0% FXN, +3.9% organic) and fiscal 2025 revenue of $21.8B (+8.2% reported, +7.7% FXN, +2.9% organic).

Q4 GAAP diluted EPS was $1.72 and adjusted diluted EPS was $3.96. Full-year GAAP EPS was $5.82 (down 0.7%) and adjusted diluted EPS was $14.40 (+9.6%). Adjusted operating margin improved to 25.0%; GAAP operating margin was 11.8%.

BD returned $2.2B to shareholders in FY25 and provided FY26 guidance of low single-digit revenue growth and adjusted diluted EPS of $14.75–$15.05. Management reiterated the planned combination of Biosciences and Diagnostic Solutions with Waters around end of Q1 CY2026.